Fixes Book Closure for Dividend & AGM
Venus Remedies Ltd has informed BSE that the Register of Members & Share Transfer Books of the Company will remain closed from September 25, 2013 to September 30, 2013 (both days inclusive) for the purpose of Payment of Dividend & Annual General Meeting (AGM) of the Company to be held on September 30, 2013. OECD-GLP Accreditation for Venus' VMRC
Venus Remedies Ltd has informed BSE regarding "OECD-GLP Accreditation for Venus' VMRC". Revised Financial Results for June 30, 2013
Venus Remedies Ltd has informed BSE about the Revised Financial Results for the period ended June 30, 2013. Financial Results & Limited Review for June 30, 2013
Venus Remedies Ltd has informed BSE about the Financial Results & a copy of the Limited Review Report for the period ended June 30, 2013. PIC / s GMP for all 9 units of Venus Remedies
Venus Remedies Ltd has informed BSE regarding "PIC / s GMP for all 9 units of Venus Remedies". Venus bags Japanese patent for Elores - The Antibiotic against Superbugs
Venus Remedies Ltd has informed BSE regarding "Venus bags Japanese patent for Elores - The Antibiotic against Superbugs". Venus Remedies among the Best Companies to Work for
Venus Remedies Ltd has informed BSE regarding "Venus Remedies among the Best Companies to Work for". Outcome of Board Meeting
Venus Remedies Ltd has informed BSE that the Board of Directors of the Company at its meeting held on June 19, 2013, inter alia, has considered & approved following:1. Allotment of 9,00,000 equity shares of Rs. 10 each to promoter group company pursuant to conversion of warrants fully convertible into equity shares.2. Re-appointment of Cost Auditor for the FY 2013-14. Venus Remedies gets Mexico patent for Potentox
Venus Remedies Ltd has informed BSE regarding "Venus Remedies gets Mexico patent for Potentox". Board recommends Dividend
Venus Remedies Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 18, 2013, inter alia, has :1. Recommended a dividend @ of 30% i.e. Rs. 3/-per share for the financial year ended March 31, 2013, subject to approval of the same by shareholders at the Annual General Meeting.2. The Board of Directors also approved raising of funds by way of equity/convertible instruments in the Company/its Wholly...